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cancer (HNPCC) but by flexible sigmoidoscopy or FOBT for lesser degrees of risk. We wished to investigate the sensitivity and specificity of HemeSelect in a group at high risk undergoing colonoscopy and the effect of adding HS to flexible sigmoidoscopy in people at lesser risk.
Methods

PATIENTS
HO and HS were examined in two groups of subjects, detailed below. Subjects were asked to complete HO and HS tests on each of three daily bowel motions before endoscopy. Rehydration of HO test cards was not performed. A blue discolouration at 30 seconds was taken as a positive reaction after the application of two drops of 1% w/w hydrogen peroxide.3 Erythrocyte agglutination at a 1:8 dilution was taken as a positive reaction for HS. 3 No dietary restriction was enforced. Participants were recruited, to the study, from an open access clinic for relatives of colorectal cancer patients and a number of case finding initiatives ongoing in our unit. Overall compliance, with endoscopy was 73% at the time of study, but many people were self referring volunteers. The male:female ratio was 1:1-58. Subjects who presented with symptoms were excluded from analysis. Among people at high levels of familial risk, although the incidence of adenomas is not especially high, their rate of conversion to cancers may be significantly increased. '7 A screening test for these people will therefore need to be sensitive for adenomas. Our study has confirmed other reportsl' 13 that found Haemoccult is not sufficiently sensitive for familial colorectal cancer screening. We found HemeSelect to be more sensitive for adenomas in this group but associated with a higher false positive rate. Its performance in this group was similar to that in symptomatic patients.3
In people with lower levels of familial risk it has been suggested that FOBT may be a useful adjunct to left sided endoscopy in screening subjects at lower levels of familial risk.'2 This has not been shown by our study, with no additional neoplasia being detected by the addition of HO and HS to 60 cm flexible sigmoidoscopy. Furthermore the high false positive rate of HS, and therefore high level of colonoscopy will add considerably to the cost of a screening programme using this test.
Detection of tumour associated antigens such as carcinoembryonic antigen18 or the protein products of tumour mutations potentially provide more specific markers, although mutant p53 has proved initially disappointing.'9 Therefore at least for the present time there is no FOBT that appears sufficiently sensitive to replace endoscopy in screening people at risk of familial colorectal cancer. 
